Caribou Biosciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CRBU | DTIL | CRSP | CLLS | RNAC | BCTX | |
|---|---|---|---|---|---|---|
| Market cap | 53.27M | 180.24M | 4.98B | 118.86M | 211.48M | 33.67M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.6 | -3.5 | -14.7 | -1.9 | -1.8 | -9.9 |
| Price/book | 0.5 | 3.8 | 2.9 | 2.1 | -1.7 | 1.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −79.63% | +11.62% | −25.70% | −71.70% | −25.80% | −66.11% |
| Today | +7.97% | −2.83% | −3.45% | −6.35% | −0.92% | −1.28% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CRBU news ›Caribou Biosciences Halts Off-the-Shelf CRISPR CAR-T Programs for Lymphoma and Myeloma After Failing to Fund Phase 3 Trial
STAT reported on Oct. 7 that the company is shutting down. Chief executive Rachel Haurwitz told STAT that Caribou had worked out a phase 3 design with the FDA, but raising money to pay for the study proved too difficult. For patients with…
Rx Rundown: McKesson, Caribou Biosciences, Viatris and more
Check out this week’s medical marketing news, dealmaking and industry chatter. Clayton, Dubilier & Rice (CD&R) and McKesson acquired Option Care Health for $5.8 billion. Viatris said it will acquire Pacira Biosciences for $1.65 billion. GE…
StockWatch: Caribou Plunges as It Pursues Strategic Alternatives
CRISPR genome-editing cell therapy developer plunges 60% on announcement of plans to assess strategic alternatives, halt clinical trials, and cut workforce ‘substantially’ A Caribou Biosciences researcher at work. Caribou, whose…
Caribou Halts Allogeneic CAR T Programs as Funding Pressures Mount
Caribou Biosciences plans to discontinue its two allogeneic CAR T-cell therapy programs and make substantial workforce reductions after struggling to secure the funding needed to continue their development. The company’s board has begun a…
Why Is CRBU Stock Crashing Today?
Shares of Caribou Biosciences (CRBU) crashed more than 35% in pre-market trading on Wednesday, as Wall Street sharply cut its price target after the biotech firm said it would scale back its cancer-drug development efforts. If levels hold…
Caribou Biosciences (NASDAQ:CRBU) Stock Dropped to Neutral by HC Wainwright
Posted by Danessa Lincoln on Oct 8th, 2026 Caribou Biosciences (NASDAQ:CRBU – Get Free Report) was downgraded by investment analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a report issued on Thursday, MarketBeat.com…
Caribou Biosciences (NASDAQ:CRBU) Stock Moved Down to Market Perform by Leerink Partners
Caribou Biosciences (NASDAQ:CRBU – Get Free Report) was downgraded by stock analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a note issued to investors on Wednesday, MarketBeat Ratings reports. They…
Read the report: S&P Global downgrades Roswell Park’s credit rating
On Oct. 1, S&P Global Ratings lowered its long-term rating on the New York State Dormitory Authorityâs bonds that were issued for Roswell Park Comprehensive Cancer Center. S&P Global lowered the rating from A- to BBB+, a downgrade but…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
defenseworld.net4
-
themarketsdaily.com3
-
tradingview.com2
-
allsci.com1
-
biopharmadive.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 29 articles, not a forecast.